Latest news with #Children'sOncologyGroup
Business Wire
07-05-2025
- Health
- Business Wire
Children's Hospital Los Angeles Leads Development of First Machine Learning Tool to Predict Risk of Cisplatin-Induced Hearing Loss
LOS ANGELES--(BUSINESS WIRE)--An international research team led by Etan Orgel, MD at Children's Hospital Los Angeles (CHLA) has developed a novel machine learning model that can predict an individual child's risk of developing hearing loss from the chemotherapy drug cisplatin. The team, which includes researchers from the Keck School of Medicine of USC and other institutions across the U.S. and Canada, is the first to develop and validate a novel machine learning model for this purpose. The tool, called PedsHEAR, uses routine, readily available information to quickly predict this risk—with 95% confidence. Results were published in the Journal of Clinical Oncology , and the model is now available for public use. Cisplatin has been used since the late 1970s to treat a variety of cancers and is highly effective against pediatric solid tumors in the brain and spinal cord, as well as neuroblastoma and rhabdomyosarcoma. Yet, cisplatin is well known to cause devastating side effects. In children, the most common side effect following therapy is debilitating, permanent hearing loss. A decades-long journey to personalize care The study grew out of two decades of efforts to prevent cisplatin-induced hearing loss in children. Investigators from CHLA led the pivotal phase 3 Children's Oncology Group trial of sodium thiosulfate (STS), and in 2022, the Food and Drug Administration approved STS as the first treatment to reduce the risk of hearing loss in children given cisplatin. But patients' treatment regimens are already highly complex, and some may not need STS to prevent hearing loss. For those who are not eligible for STS, it's critical for clinicians to understand each patient's risk and what options they have to protect that child's hearing. 'We want to give families and providers the tools they need to understand their child's risk and make an informed decision,' explains Dr. Orgel, who directs Quality and Patient Safety at CHLA's Cancer and Blood Disease Institute. 'This is the paradigm shift we're aiming for—speaking in certainties for each child versus speaking in generalities by regimen.' This new predictive model is informed by a landmark study designed and led by Dr. Orgel in 2021. Researchers analyzed data from more than 1,400 cisplatin-treated patients across the United States and Canada to establish the first benchmarks for the prevalence of cisplatin-induced hearing loss in children and adolescents. Researchers used the 1,400-person dataset as the foundation for the PedsHEAR model, training it to analyze risk factors and probabilities and accurately predict a child's risk level for hearing loss. The researchers also brought in two new, real-world data sets from the Children's Oncology Group and a children's hospital in Texas to validate the model in other populations. The now publicly available web model provides each patient with a percentage indicating the child's individual probability of hearing loss. Creating a new treatment planning standard 'My goal is for this to become a routine clinical tool,' says Dr. Orgel. 'What's unique about this model is that it only uses routinely available data, so any doctor can use it from day one of diagnosis to plan treatment.' He adds, 'Ultimately, we aim to expand our approach to understand and predict risk for other common side effects of common chemotherapies. 'We want to equip all patients beginning their cancer journey with knowledge that supports meaningful discussions with their doctors on what to expect during and after treatment.' The research team's next goal is to expand the model to young adults and adults up to 65 and to integrate genomics to make the model's output even more precise. About Children's Hospital Los Angeles Founded in 1901, Children's Hospital Los Angeles is at the forefront of pediatric medicine and is the largest provider of hospital care for children in California. Children's Hospital is home to renowned experts who work together across disciplines to deliver inclusive and compassionate care, and drive advances that set pediatric standards across the nation and around the globe. Children's Hospital Los Angeles delivers a level of care that is among the best in the world for a truly diverse population of children. The hospital is consistently ranked in the top 10 in the nation on U.S. News & World Report's Honor Roll of Best Children's Hospitals. CHLA is the top-ranked children's hospital in California and the Pacific U.S. region for 2024-25. Children's Hospital Los Angeles embraces the hospital's mission to create hope and build healthier futures. Children's Hospital Los Angeles is among the top 10 children's hospitals for National Institutes of Health funding. The Saban Research Institute of Children's Hospital Los Angeles supports the full continuum of research, allowing physicians and scientists to translate discoveries into treatments and bring answers to families faster. The pediatric academic medical center also is home to one of the largest training programs for pediatricians in the United States. And the hospital's commitment to building strong communities is evident in CHLA's efforts to fight food insecurity, enhance health education and literacy, and introduce more people to careers in health care. To learn more, follow CHLA on Facebook , Instagram, LinkedIn, YouTube, and X , formerly known as Twitter, and visit
Yahoo
29-01-2025
- Health
- Yahoo
Groundbreaking pediatric leukemia treatment now available in Wichita
WICHITA, Kan. (KSNW) — KU School of Medicine-Wichita Department of Pediatrics and Wesley Children's Hospital say a groundbreaking treatment for pediatric leukemia is now available in Wichita. Blinatumomab, which recently completed clinical trials and has won approval from the FDA, is a drug designed to treat acute lymphoblastic leukemia, one of the most common types of blood and bone marrow cancer. It causes the body to produce too many lymphocytes, a type of white blood cell. The disease has a rapid onset. If left untreated, death can happen within a matter of months. Blinatumomab uses the patient's immune system to fight the disease. It teaches the body's T-cells, a type of white blood cell, to recognize and destroy leukemia cells. The tuberculosis outbreak in Kansas is alarming. It's not the biggest in US history though, CDC says Clinical trials showed the average risk of relapse, and survival rates rose to 97.5% with the new drug regimen vs. 90.2% for those without blinatumomab. For high-risk patients, the rate rose from 84.8% to 94.1%. 'This treatment is a transformative step forward for children in our community,' says Nathan Hall, D.O., MBA, M.S., associate professor and director of pediatric hematology and oncology at KU Wichita Pediatrics and Wesley Medical Center. 'For families facing the challenge of a leukemia diagnosis, this therapy offers new possibilities and a hope for one day curing all pediatric cancer.' The treatment is now available thanks to a partnership between the KU School of Medicine-Wichita Department of Pediatrics, Wesley Children's Hospital and Children's Oncology Group. 'This partnership aligns with our mission to provide comprehensive, family-centered care while pushing the boundaries of what is possible in pediatric medicine,' says Brian Pate, M.D., chair of the Department of Pediatrics at KU School of Medicine-Wichita. 'Families no longer need to seek care outside the state to access treatments. Instead, they can receive world-class care right here in Wichita, and we are also using these opportunities to train future pediatricians in the only pediatric training program in Kansas.' The Children's Oncology Group is a member of the National Cancer Institute National Clinical Trials Group, the world's largest organization devoted exclusively to childhood and adolescent cancer research. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
